Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Jan;32(1):137–140. doi: 10.1128/aac.32.1.137

Antimicrobial susceptibilities of Bordetella species isolated in a Multicenter Pertussis Surveillance Project.

T A Kurzynski 1, D M Boehm 1, J A Rott-Petri 1, R F Schell 1, P E Allison 1
PMCID: PMC172115  PMID: 2894817

Abstract

MICs for 90% (MIC90s) of 75 Bordetella pertussis strains for amoxicillin, erythromycin, rifampin, and sulfamethoxazole-trimethoprim were 1, less than or equal to 0.12, 1, and 4 micrograms/ml, respectively. Susceptibility rates were all greater than or equal to 93%. Only 17% of the strains were susceptible to tetracycline. The MIC90s of ciprofloxacin, enoxacin, norfloxacin, ofloxacin, and roxithromycin were less than or equal to 0.06, 0.5, 0.25, 0.12, and 0.5 micrograms/ml, respectively. For B. parapertussis, the MIC90s were 16-fold higher with amoxicillin and rifampin and 2- to 4-fold higher with the fluoroquinolones and roxithromycin.

Full text

PDF
139

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arneil G. C., McAllister T. A. Whooping-cough in infants: Antimicrobial prophylaxis? Lancet. 1977 Jul 2;2(8027):33–34. doi: 10.1016/s0140-6736(77)90021-6. [DOI] [PubMed] [Google Scholar]
  2. Bannatyne R. M., Cheung R. Antibiotic resistance of degraded strains of Bordetella pertussis. Antimicrob Agents Chemother. 1984 Apr;25(4):537–538. doi: 10.1128/aac.25.4.537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bannatyne R. M., Cheung R. Antimicrobial susceptibility of Bordetella pertussis strains isolated from 1960 to 1981. Antimicrob Agents Chemother. 1982 Apr;21(4):666–667. doi: 10.1128/aac.21.4.666. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bannatyne R. M., Cheung R. Susceptibility of Bordetella pertussis to cephalosporin derivatives and imipenem. Antimicrob Agents Chemother. 1984 Oct;26(4):604–605. doi: 10.1128/aac.26.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bass J. W., Crast F. W., Kotheimer J. B., Mitchell I. A. Susceptibility of Bordetella pertussis to nine antimicrobial agents. Am J Dis Child. 1969 Mar;117(3):276–280. doi: 10.1001/archpedi.1969.02100030278004. [DOI] [PubMed] [Google Scholar]
  6. Boppana V. K., Swanson B. N. Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother. 1982 May;21(5):808–810. doi: 10.1128/aac.21.5.808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Crump B., Wise R., Dent J. Pharmacokinetics and tissue penetration of ciprofloxacin. Antimicrob Agents Chemother. 1983 Nov;24(5):784–786. doi: 10.1128/aac.24.5.784. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cullen A. S., Cullen H. B. Whooping-cough: Prophylaxis with co-trimoxazole. Lancet. 1978 Mar 11;1(8063):556–556. doi: 10.1016/s0140-6736(78)90579-2. [DOI] [PubMed] [Google Scholar]
  9. Fuchs P. C., Barry A. L., Jones R. N., Thornsberry C. Proposed disk diffusion susceptibility criteria for ofloxacin. J Clin Microbiol. 1985 Aug;22(2):310–311. doi: 10.1128/jcm.22.2.310-311.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lautrop H. Epidemics of parapertussis. 20 years' observations in Denmark. Lancet. 1971 Jun 12;1(7711):1195–1198. doi: 10.1016/s0140-6736(71)91713-2. [DOI] [PubMed] [Google Scholar]
  11. Linnemann C. C., Perry E. B. Bordetella parapertussis. Recent experience and a review of the literature. Am J Dis Child. 1977 May;131(5):560–563. doi: 10.1001/archpedi.1977.02120180074014. [DOI] [PubMed] [Google Scholar]
  12. Mertsola J. Mixed outbreak of Bordetella pertussis and Bordetella parapertussis infection in Finland. Eur J Clin Microbiol. 1985 Apr;4(2):123–128. doi: 10.1007/BF02013576. [DOI] [PubMed] [Google Scholar]
  13. Papasian C. J., Downs N. J., Talley R. L., Romberger D. J., Hodges G. R. Bordetella bronchiseptica bronchitis. J Clin Microbiol. 1987 Mar;25(3):575–577. doi: 10.1128/jcm.25.3.575-577.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Rudrik J. T., Cavalieri S. J., Britt E. M. In vitro activities of enoxacin and 17 other antimicrobial agents against multiply resistant, gram-negative bacteria. Antimicrob Agents Chemother. 1984 Jul;26(1):97–100. doi: 10.1128/aac.26.1.97. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Terakado N., Azechi H., Ninomiya K., Shimizu T. Demonstration of R factors in Bordetella bronchiseptica isolated from pigs. Antimicrob Agents Chemother. 1973 May;3(5):555–558. doi: 10.1128/aac.3.5.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Trollfors B. Effect of erythromycin and amoxycillin on Bordetella pertussis in the nasopharynx. Infection. 1978;6(5):228–230. doi: 10.1007/BF01642314. [DOI] [PubMed] [Google Scholar]
  17. Zackrisson G., Brorson J. E., Björnegård B., Trollfors B. Susceptibility of Bordetella pertussis to doxycycline, cinoxacin, nalidixic acid, norfloxacin, imipenem, mecillinam and rifampicin. J Antimicrob Chemother. 1985 May;15(5):629–632. doi: 10.1093/jac/15.5.629. [DOI] [PubMed] [Google Scholar]
  18. Zackrisson G., Brorson J. E., Krantz I., Trollfors B. In-vitro sensitivity of Bordetella pertussis. J Antimicrob Chemother. 1983 May;11(5):407–411. doi: 10.1093/jac/11.5.407. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES